MedTrace Logo

Urdu Translation And Cross-Cultural Validation of the Foot And Ankle Disability Index

NCT05732636 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-08-15

No results posted yet for this study

Summary

The goal of this Cross-cultural validation study is to Urdu translate and cross-cultural validation of Foot and Ankle Disability Index for the Patients with Chronic Ankle Instability. The main question it aims to answer was:

• To Translate Foot and Ankle Disability Index in Urdu and to find out the Validity and Reliability for Patients with Chronic Ankle Instability.

Data collection procedure would be, FADI Urdu version was introduced and the patients were asked to fill FADI Urdu version. The questionnaire was filled again by the same participants after one week to assess the test retest reliability. Questionnaire was conducted to have the best result. After the ethical approval, participants who meet the inclusion criteria and who were free from exclusion criteria were explained about the objectives of this study. Only those who gave consent were included in the study.

Conditions

  • Ankle Disorders Injuries

Interventions

OTHER

Validation study

The whole protocol is divided into two stages: Urdu Translation and validation. Following steps were involved. 1. First version (Forward Translation): Forward translation from the English to Urdu by two bilingual translators (Version 1) 2. Second Version: Three experts compared the original FADI with urdu version of FADI. 3. Backward translation: Version 2 was translated Back in English by an independent translator. 4. Third Version: was finalized after tracking differences in forward and backward translation. 5. Final Version: of Urdu FADI was used on Chronic Ankle Instability patients. Foot and Ankle Disability Index(FADI) Urdu version was introduced and the patients were asked to fill FADI Urdu version. The questionnaire was filled again by the same participants after one week to assess the test retest reliability.

Sponsors & Collaborators

  • Sehat Medical Complex

    lead OTHER

Principal Investigators

  • Saira Akbar Bodla, MS-SPT · Riphah International University

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-28
Primary Completion
2023-06-30
Completion
2023-07-25

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05732636 on ClinicalTrials.gov